WHAT IS KNOWN AND OBJECTIVE: Echinocandins are antifungal agents, routinely used in invasive candida infections in critically ill patients. Their excellent anticandidal activity and their low frequency of reported adverse events and drug interactions make them first-line guideline treatments of candidiasis especially in intensive care units (ICU). We report on three ICU patients who developed cardiac insufficiency and hemodynamic instability during administration of loading doses of an echinocandin. CASE SUMMARY: Three ICU patients showed a substantial drop in their cardiac index or a deterioration of the mean arterial pressure following start of echinocandin administration. The patients were 75 years (female), 71 years (male) and 66 years (male) old. One patient received caspofungin, and two patients received anidulafungin as empirical antifungal treatment for severe sepsis. WHAT IS NEW AND CONCLUSION: Our cases suggest that the observed cardiac impairment could be associated with echinocandin administration. Therefore, we recommend close hemodynamic monitoring of critically ill patients receiving echinocandins.
WHAT IS KNOWN AND OBJECTIVE:Echinocandins are antifungal agents, routinely used in invasive candida infections in critically illpatients. Their excellent anticandidal activity and their low frequency of reported adverse events and drug interactions make them first-line guideline treatments of candidiasis especially in intensive care units (ICU). We report on three ICU patients who developed cardiac insufficiency and hemodynamic instability during administration of loading doses of an echinocandin. CASE SUMMARY: Three ICU patients showed a substantial drop in their cardiac index or a deterioration of the mean arterial pressure following start of echinocandin administration. The patients were 75 years (female), 71 years (male) and 66 years (male) old. One patient received caspofungin, and two patients received anidulafungin as empirical antifungal treatment for severe sepsis. WHAT IS NEW AND CONCLUSION: Our cases suggest that the observed cardiac impairment could be associated with echinocandin administration. Therefore, we recommend close hemodynamic monitoring of critically illpatients receiving echinocandins.
Authors: C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2015-09 Impact factor: 1.041
Authors: A Brinkmann; A C Röhr; A Köberer; T Fuchs; W A Krüger; C König; D Richter; M A Weigand; O R Frey Journal: Anaesthesist Date: 2018-06 Impact factor: 1.041
Authors: Christian Koch; Emmanuel Schneck; Christoph Arens; Melanie Markmann; Michael Sander; Michael Henrich; Markus A Weigand; Christoph Lichtenstern Journal: Int J Clin Pharm Date: 2019-11-21
Authors: Christian Koch; Jennifer Jersch; Emmanuel Schneck; Fabian Edinger; Hagen Maxeiner; Florian Uhle; Markus A Weigand; Melanie Markmann; Michael Sander; Michael Henrich Journal: Antimicrob Agents Chemother Date: 2018-10-24 Impact factor: 5.191
Authors: Christian Koch; Florian Uhle; Matthias Wolff; Christoph Arens; Astrid Schulte; Ling Li; Bernd Niemann; Michael Henrich; Susanne Rohrbach; Markus A Weigand; Christoph Lichtenstern Journal: Antimicrob Agents Chemother Date: 2014-12-29 Impact factor: 5.191
Authors: Tobias Lahmer; Christopher Schnappauf; Marlena Messer; Sebastian Rasch; Lisa Fekecs; Analena Beitz; Stefan Eser; Roland M Schmid; Wolfgang Huber Journal: Infection Date: 2015-08-11 Impact factor: 3.553
Authors: Christian Koch; Matthias Wolff; Michael Henrich; Markus A Weigand; Christoph Lichtenstern; Florian Uhle Journal: Antimicrob Agents Chemother Date: 2015-10-26 Impact factor: 5.191
Authors: Sabrina Müller; Christian Koch; Sebastian Weiterer; Markus A Weigand; Michael Sander; Michael Henrich Journal: Sci Rep Date: 2020-07-16 Impact factor: 4.379